RALLYBIO CORP
NASDAQ: RLYB (Rallybio Corporation)
Kemas kini terakhir: 2 jam lalu17.02
0.03 (0.18%)
| Penutupan Terdahulu | 16.99 |
| Jumlah Dagangan | 6,941 |
| Harga / Jualan (P/S) | 148.13 |
| Harga / Buku (P/B) | 0.950 |
| Julat 52 Minggu |
| Margin Operasi (TTM) | -4,561.32% |
| EPS Cair (TTM) | -1.07 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.22% |
| Nisbah Semasa (MRQ) | 14.68 |
| Aliran Tunai Operasi (OCF TTM) | -44.03 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -28.16 M |
| Pulangan Atas Aset (ROA TTM) | -40.02% |
| Pulangan Atas Ekuiti (ROE TTM) | -67.28% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Rallybio Corporation | Bercampur | Bercampur |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 2.0 |
| Purata | 0.00 |
|
Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 4.16% |
| % Dimiliki oleh Institusi | 76.90% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Viking Global Investors Lp | 30 Jun 2026 | 524,347 |
| Tpg Gp A, Llc | 30 Jun 2026 | 378,551 |
| Pivotal Bioventure Partners Investment Advisor Llc | 30 Jun 2026 | 300,579 |
| Renaissance Technologies Llc | 30 Jun 2026 | 199,907 |
| Nantahala Capital Management, Llc | 30 Jun 2026 | 188,422 |
| Almitas Capital Llc | 30 Jun 2026 | 120,682 |
| Rangeley Capital, Llc | 30 Jun 2026 | 104,850 |
| Aju Ib Investment Co., Ltd. | 31 Mar 2026 | 94,334 |
| Citadel Advisors Llc | 30 Jun 2026 | 72,200 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| LIEBER JONATHAN I | - | - | 0 | 0 |
| Jumlah Keseluruhan Kuantiti Bersih | 0 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | 0 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | - | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| LIEBER JONATHAN I | Pegawai | 29 Sep 2026 | Pelaksanaan pilihan | 5,000 | - | - |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |